Replies to post #311 on KalVista Pharmaceuticals (KALV)

[Toxic Avenger]

Yeah, it was a paint at the end of the day. Typical of many stocks heading into a weekend. It will be back down on Monday.

The stock is undervalued based on liquidation, but for whatever reason, the company decided to throw it's large cash reserve into acquiring another bio tech which needs cash. And all they get is 20% of the company for that cash. That values KalVista at about $175 million, which clearly the market thinks is too high.
Based on CBYL's current price, the market values KalVista at about $70 million.

Definitely not zero risk as KalVista is just starting its phase 1 clinical trials on their one drug and results won't be announced until Q2 2017.